IBD-associated healthcare activity per 1000 patients from 2010 to 2017 and predicted to 2022
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | P value and R value | |
| Prevalence | 2500 | 2606 | 2698 | 2792 | 2892 | 3013 | 3124 | 3204 | |
| Outpatient clinic appointments | 396 | 413.7 | 500.7 | 491.1 | 537.34 | 592.43 | 636.01 | 624.18 | p=5.2e-5 R=0.97 |
| Inflammatory bowel disease helpline calls* | 1206.1 | 1400.9 | 1445.4 | 1462.7 | p=0.07 R=0.85 | ||||
| Emergency hospital admissions under gastroenterological care | 29.2 | 31.08 | 34.84 | 31.88 | 39.42 | 37.84 | 39.41 | 31.87 | p=0.18 R=0.53 |
| Mean length of stay (days) | 7 | - | – | – | 9 | – | – | 6 | N/A |
| Patients on biological therapy | 45.8 | 56.6 | 93.5 | 114 | 102.9 | 122.7 | 141 | 148.3 | p=1.3e-4 R=0.96 |
| Infliximab | 33.2 | 36.9 | 61.3 | 71.8 | 59.5 | 72.0 | 68.7 | - | |
| Adalimumab | 12.6 | 19.8 | 32.1 | 42.2 | 43.5 | 31.4 | 34.4 | - | |
| Vedolizumab | - | - | - | - | - | 12.7 | 25.7 | - | |
| Golilumab | - | - | - | - | - | 4.0 | 8.7 | - | |
| Ustekinumab | - | - | - | - | - | – | 2.9 | - | |
| Endoscopies (all lower gastroentestinal) | 196.5 | 253.3 | 284.9 | 265.8 | 267.7 | 303.9 | 273.7 | 236.1 | p=0.34 R=0.39 |
| Capsule endoscopies | – | - | - | - | 16.3 | 19.0 | 18.6 | 17.1 | N/A |
| Surgical resections | 19.9 | 26.4 | 19.4 | 23.8 | 18.1 | 20.0 | 19.0 | 16.8 | p=0.13 R=−0.58 |
| Radiological imaging | |||||||||
| CT | 84.3 | 76.8 | 90.8 | 100.6 | 100.8 | 91.7 | 90.3 | 81.6 | p=0.68 R=0.18 |
| MR | 24.3 | 50.8 | 36.6 | 46.9 | 53.9 | 61.7 | 54.3 | 54.8 | p=0.03 R=0.76 |
| US | 67.3 | 76 | 78.1 | 78.6 | 71.3 | 87.1 | 66.5 | 62.6 | p=0.6 R=−0.22 |
| Barium | 39.7 | 23.3 | 22.1 | 11.9 | 7.0 | 5.3 | 5.1 | 0.9 | p=9.0e-4 R=0.86 |
Clinics, admissions, endoscopies and imaging are reported as annual number of episodes per 1000 patients with IBD. Biologics are reported as annual number of patients issued biological therapy per 1000 patients with IBD. P refers to the p value of the gradient in a linear regression model.
*Helpline calls are shown as total calls received within the year.
CT, computed tomography; MRI, magnetic resonance; US, ultrasound.